"An investment in knowledge pays the best interest."

UPDATES ON AN ARTIFICIAL INTELLIGENCE DIGITAL HEALTHCARE SOLUTION 

 

Diagnos Inc. (ADK.V) reported it has successfully screened over 71,000 diabetic patients and received payments on time for services.

The 2016 contract covered ISSSTE's diabetic population from Mexico City and the metropolitan area. Over 71,000 diabetes patients were screened in record time in order to help prevent patients from going blind and accelerate referral for treatment to safeguard patients' health.

"Diagnos's artificial intelligence platform (CARA) delivered outstanding results during the screening operations, demonstrating the efficiency of our solution. The data collected will be very valuable to our clients in identifying further actions to be taken with their diabetic population. We would like to thank ISSSTE's leadership and the Mexican government for taking the lead in preventing blindness and trusting our artificial intelligence services, which will help reduce and streamline diabetes costs," said Andre Larente, chief executive officer of Diagnos.

ISSSTE is the health and social services institution for the federal government employees. It covers over 13 million people across the nation. For 2017, the objective is to work with ISSSTE and cover three times the volume of 2016 and to expand national coverage by supporting its MIDE flagship diabetes program.

About Diagnos

Diagnos offers products, services and solutions to clients in a variety of fields, including health care and natural resources.

About CARA (computer-assisted retinal analysis)

CARA is a teleophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated prescreening, grading by a specialist and referral to a specialist. CARA is a cost-effective tool for screening large numbers of patients in real time and has been approved by regulatory authorities, including Health Canada, the U.S. Food and Drug Administration, European Union (CE), and COFEPRIS for Mexico.